CAY10594

CAY10594 is an orally active PLD2 inhibitor with an IC50 of 140 nM. CAY10594 has activities such as anti-tumor, anti-oxidation and liver protection. CAY10594 can be used for the research of diseases like breast cancer, acute liver injury and colitis[1][2][3][4].

Product Specifications

CAS Number

[1130067-34-3]

UNSPSC

12352005

Target

Anaplastic lymphoma kinase (ALK) ; Apoptosis; CXCR; G Protein-coupled Receptor Kinase (GRK) ; GSK-3; Interleukin Related; Lactate Dehydrogenase; Phospholipase; STAT

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein; Immunology/Inflammation; JAK/STAT Signaling; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/cay10594.html

Purity

98.64

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(C1=CC2=C(C=C1)C=CC=C2)NCCN3CCC4(CC3)C(NCN4C5=CC=CC=C5)=O

Molecular Formula

C26H28N4O2

Molecular Weight

428.53

References & Citations

[1]Scott SA, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5 (2) :108-17.|[2]Lee SK, et al. A phospholipase D2 inhibitor, CAY10594, ameliorates acetaminophen-induced acute liver injury by regulating the phosphorylated-GSK-3β/JNK axis. Sci Rep. 2019 May 10;9 (1) :7242. |[3]Qian T, et al. PLD2 deletion alleviates disruption of tight junctions in sepsis-induced ALI by regulating PA/STAT3 phosphorylation pathway. Int Immunopharmacol. 2023 Jan;114:109561.|[4]Zhou G, et al. Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of Inflammatory Bowel Disease. Mediators Inflamm. 2016;2016:2543070.